Bronte Capital Management Pty Ltd. Regeneron Pharmaceuticals, Inc. Transaction History
Bronte Capital Management Pty Ltd.
- $1.12 Billion
- Q3 2024
A detailed history of Bronte Capital Management Pty Ltd. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bronte Capital Management Pty Ltd. holds 137,042 shares of REGN stock, worth $112 Million. This represents 12.83% of its overall portfolio holdings.
Number of Shares
137,042
Previous 139,454
1.73%
Holding current value
$112 Million
Previous $147 Million
1.71%
% of portfolio
12.83%
Previous 12.41%
Shares
16 transactions
Others Institutions Holding REGN
# of Institutions
1,490Shares Held
85.8MCall Options Held
908KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$7.34 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.9 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$6.76 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$3.95 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$3.79 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $87.5B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...